Breed · Horse
Standardbred: adverse event reports
FDA breed label "Standardbred (unspecified)" · single-breed animals only
FDA's database holds 347 reports where the animal's breed is given as "Standardbred (unspecified)", shown here as Standardbred: 1.9% of reports about horses. Reports on crossbred animals are left out of breed pages.
7 reports arrived in the 12 months to March 2026, up 600% from 1 in the 12 months before. A breed's count mostly mirrors how common the breed is; registration and ownership figures by breed are not public data, so no per-animal rate can be given.
By active ingredient, the drugs named most often are hyaluronate sodium, ivermectin + praziquantel and omeprazole. Hyaluronate Sodium is named in 9.8% of this breed's reports, a larger share than in reports about all horses (2.9%).
The terms listed most often are fever (10.4%), death (9.8%) and death by euthanasia (8.6%). Fever appears in 10.4% of reports, a larger share than in all horse reports (4.5%). 45% of reports stating seriousness were classed as serious, against 44.1% for horses overall.
Drugs named most often, by active ingredient
| Active ingredients recorded for the drug | Reports | Share of Standardbred reports | Share of all horse reports |
|---|---|---|---|
| Hyaluronate Sodium | 34 | 9.8% | 2.9% |
| Ivermectin + Praziquantel | 30 | 8.6% | 14.4% |
| Omeprazole | 29 | 8.4% | 9.9% |
| Ceftiofur Crystalline Free Acid | 24 | 6.9% | 4.8% |
| Ivermectin | 19 | 5.5% | 4.6% |
| Vitamin E | 14 | 4% | 0.8% |
| Ketamine Hydrochloride | 12 | 3.5% | 3.3% |
| Pyrantel Tartrate | 12 | 3.5% | 4% |
| Nitazoxanide | 11 | 3.2% | 0.4% |
| Flunixin Meglumine | 10 | 2.9% | 3.5% |
| Moxidectin | 10 | 2.9% | 7.4% |
| Ceftiofur Sodium | 7 | 2% | 0.7% |
| Pergolide mesylate | 7 | 2% | 6.5% |
| Xylazine | 7 | 2% | 2.4% |
| Detomidine Hydrochloride | 6 | 1.7% | 5.6% |
| Gentamicin Sulfate | 6 | 1.7% | 0.4% |
| Methylprednisolone Acetate | 6 | 1.7% | 0.5% |
| Triamcinolone Acetonide | 6 | 1.7% | 0.6% |
| Moxidectin + Praziquantel | 5 | 1.4% | 2% |
| Phenylbutazone | 5 | 1.4% | 0.8% |
Ordered by report count. Differences from the species column often come from body size (which drugs a breed is prescribed) and from how common the breed was in the years a drug sold most. FDA states that these data cannot be used to estimate risk or to compare one product with another. Brand and manufacturer names are masked by FDA in these records.
Signs listed in reports
share of Standardbred reports listing the termall horse reports
- Fever10.4%36
- Death9.8%34
- Death by euthanasia[the animal was euthanized]8.6%30
- Abdominal pain8.1%28
- Lameness7.5%26
- Injection site swelling[swelling where the injection was given]7.2%25
- Diarrhoea[diarrhea]6.9%24
- Anorexia[not eating]6.6%23
- Joint effusion6.6%23
- Joint swelling6.6%23
- Depression[dull, quiet or withdrawn]6.3%22
- Ineffective, gastric ulcer(s)[legacy FDA term: the product did not have the expected effect (gastric ulcer(s))]5.5%19
- Recumbency[lying down and unable or unwilling to rise]5.5%19
- Anaphylaxis[sudden severe allergic-type reaction]4.9%17
- Collapse4.6%16
- Ataxia[unsteady, uncoordinated movement]4.3%15
- Lack of efficacy - NOS[the product did not have the expected effect]4.3%15
- Injection site pain[pain where the injection was given]4%14
- Application site swelling[swelling where the product was applied]3.5%12
- Joint inflammation3.5%12
- Tachycardia[fast heart rate]3.5%12
- Lip oedema3.2%11
- Tachypnoea[fast breathing]3.2%11
- Joint pain2.9%10
- Hypoproteinaemia[low blood protein]2.6%9
Age and weight
Age of the animal
Weight of the animal
Coloured bar: Standardbred reports. Grey bar: all horse reports.
Trend and outcomes
Reports by month FDA received them. The newest months are incomplete because FDA posts reports with a delay of three to six months.
Outcome recorded in the report
Beside all horses
| Measure | Standardbred | All horses |
|---|---|---|
| Reports | 347 | 18,382 |
| Latest 12 months | 7 | 898 |
| Classed serious, of reports stating it | 45% | 44.1% |
| Death or euthanasia recorded, per 1,000 reports | 190.2 | 136 |
Questions about Standardbred reports
How many FDA adverse event reports involve Standardbreds?
347 reports through March 2026, 1.9% of reports about horses; 7 in the latest 12 months.
Which drugs are named most often in Standardbred reports?
By active ingredient: hyaluronate sodium (34), ivermectin + praziquantel (30), omeprazole (29), ceftiofur crystalline free acid (24) and ivermectin (19). Brands are masked in the public data.
What signs are reported most for this breed?
fever (10.4%), death (9.8%), death by euthanasia (8.6%), abdominal pain (8.1%) and lameness (7.5%).
Is the Standardbred more sensitive to certain drugs?
Report counts cannot answer that. They show what was reported, not what a drug did, and they are not adjusted for how many Standardbred animals exist or were treated. Breed-related drug sensitivities that are established are described on FDA-approved labels; a veterinarian is the person to ask about an individual animal.
Why are crossbreds not included?
FDA records crossbred animals with one or more component breeds. Counting them under each component would double count, so breed pages use single-breed reports only. Crossbreds remain in the species totals.
How do I report a problem?
Call the drug company using the number on the label, or send Form FDA 1932a to FDA. See the guide on how to report.
Where this comes from. Counts are built from the openFDA Animal & Veterinary adverse event bulk files released 28 Sep 2026, which hold reports FDA's Center for Veterinary Medicine received through 31 Mar 2026. openFDA masks brand and manufacturer names in these files, so drugs are counted by the active ingredients each record discloses and no figure is attributed to a brand, application or company. Ingredient names, and the separate reference lists of approved products, follow the FDA Green Book as of 1 Oct 2026. Breed names are FDA's labels rearranged into everyday order ("Standardbred (unspecified)" becomes "Standardbred"). No report text, lot numbers or reporter details are published. See the methodology and sources; FDA's record is authoritative, and corrections are handled within five working days.